What is the clinical significance of the long-term results from the EPCORE NHL-2 trial of epcoritamab + R-CHOP for previously untreated high-risk DLBCL?
Lymphoma Hub19 Jun 2025

What is the clinical significance of the long-term results from the EPCORE NHL-2 trial of epcoritamab + R-CHOP for previously untreated high-risk DLBCL?

During the 18th International Conference on Malignant Lymphomas (ICML), Jun 17–21, 2025, Lugano, CH, the Lymphoma Hub was pleased to speak with Joshua Brody from the Icahn School of Medicine at Mount Sinai, New York, US. We asked about the clinical significance of the long-term results from the EPCORE NHL-2 (NCT04663347) trial, which evaluated epcoritamab (epcor) in combination with rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and prednisone (R-CHOP) in patients with B-cell non-Hodgkin lymphoma.


During this interview, Dr Joshua Brody discussed the latest data presented at the 18th ICML 2025 from the EPCORE NHL-2 study, with a focus on the cohort of patients with high-risk diffuse large B-cell lymphoma (DLBCL) treated with epcor + R-CHOP as frontline therapy. Brody highlighted the significance of durable remission in this difficult-to-treat population, provided an overview of the top-line data from the trial, and discussed upcoming developments, including the phase III randomized EPCORE DLBCL-2 (NCT05578976) trial, which is currently underway and will further evaluate the efficacy and safety of adding epcor to standard R-CHOP in this high-risk patient population.


This educational resource is independently supported by AbbVie. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.

Hosted on Acast. See acast.com/privacy for more information.

Denne episoden er hentet fra en åpen RSS-feed og er ikke publisert av Podme. Den kan derfor inneholde annonser.

Episoder(53)

Symposium |Optimizing chronic lymphocytic leukemia management in a changing landscape

Symposium |Optimizing chronic lymphocytic leukemia management in a changing landscape

On June 22, 2026, the Lymphoma Hub held a virtual symposium, titled Optimizing treatment for chronic lymphocytic leukemia with BTK inhibitors. During the symposium, Lymphoma Hub Steering Committee mem...

20 Aug 23min

Symposium | BTK inhibitors in practice: Treatment selection and emerging clinical evidence

Symposium | BTK inhibitors in practice: Treatment selection and emerging clinical evidence

On June 22, 2026, the Lymphoma Hub held a virtual symposium, titled Optimizing treatment for chronic lymphocytic leukemia with BTK inhibitors. During the symposium, Farrukh Awan, University of Texas S...

12 Aug 27min

Symposium | BTK inhibitors in CLL: Mechanisms, clinical considerations, and unmet needs

Symposium | BTK inhibitors in CLL: Mechanisms, clinical considerations, and unmet needs

On June 22, 2026, the Lymphoma Hub held a virtual symposium, titled Optimizing treatment for chronic lymphocytic leukemia with BTK inhibitors. During the symposium, Lymphoma Hub Steering Committee mem...

12 Aug 12min

EHA 2026 | What are the key findings from the DALY 2-EU trial of zamto-cel in R/R LBCL?

EHA 2026 | What are the key findings from the DALY 2-EU trial of zamto-cel in R/R LBCL?

The Lymphoma Hub was pleased to speak with Gloria Iacoboni, Vall d'Hebron University Hospital, Barcelona, ES. We asked, What are the key findings from the DALY 2-EU trial of zamtocabtagene autoleucel ...

21 Jul 8min

EHA2026 | What are the key findings from the subgroup analysis of the EPCORE FL-1 trial in R/R FL?

EHA2026 | What are the key findings from the subgroup analysis of the EPCORE FL-1 trial in R/R FL?

Following the European Hematology Association (EHA) 2026 Congress, June 11–14, 2026, Stockholm, SE, the Lymphoma Hub spoke with Lorenzo Falchi, Memorial Sloan Kettering Cancer Center, New York, US. We...

16 Jul 10min

Zanubrutinib for patients with previously untreated CLL/SLL: Insights from the SEQUOIA trial

Zanubrutinib for patients with previously untreated CLL/SLL: Insights from the SEQUOIA trial

During the Lymphoma Hub Steering Committee Meeting on April 20, 2026, key opinion leaders met to discuss results from the long-term follow-up of the phase III SEQUOIA trial (NCT03336333) evaluating za...

10 Jul 26min

EHA 2026 | What are the key findings from the phase I ANTLER trial in R/R B-cell NHL?

EHA 2026 | What are the key findings from the phase I ANTLER trial in R/R B-cell NHL?

During the European Hematology Association (EHA) 2026 Congress, June 11–14, 2025, Stockholm, SE, the Lymphoma Hub spoke with Stephen Schuster, University of Pennsylvania, Philadelphia, US. We asked, W...

1 Jul 5min

Annual oncology meeting | Key highlights in lymphoma

Annual oncology meeting | Key highlights in lymphoma

During the American Society of Clinical Oncology Annual Meeting, May 19 – June 2, 2026, Chicago, US, the Lymphoma Hub was pleased to speak with Joshua Brody from the Icahn School of Medicine at Mount ...

22 Jun 11min

Populært innen Fakta

fastlegen
dine-penger-pengeradet
relasjonspodden-med-dora-thorhallsdottir-kjersti-idem
treningspodden
rss-strid-de-norske-borgerkrigene
jakt-og-fiskepodden
foreldreradet
rss-orjasater
hverdagspsyken
sinnsyn
tomprat-med-gunnar-tjomlid
rss-kunsten-a-leve
mikkels-paskenotter
rss-var-forste-kaffe
lederskap-nhhs-podkast-om-ledelse
gravid-uke-for-uke
fryktlos
rss-impressions-2
kvallm
branncast